(Q36568861)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16916489%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

review article

1 reference

title

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16916489%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16916489%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Thomas E Witzig

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16916489%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16916489%20AND%20SRC:MED&resulttype=core&format=json

Current Treatment Options in Oncology

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16916489%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16916489%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

285-294

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16916489%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16916489%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11864-006-0038-1

28 December 2019

exact match

0 references

cites work

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-006-0038-1

Mechanism of activation of protein kinase B by insulin and IGF-1

21 January 2018

1 reference

12 December 2020

Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling

1 reference

12 December 2020

Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells

1 reference

12 December 2020

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway

1 reference

12 December 2020

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

12 December 2020

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

1 reference

12 December 2020

Putting the rap on Akt.

1 reference

12 December 2020

Upstream and downstream of mTOR

1 reference

12 December 2020

Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation

1 reference

12 December 2020

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

1 reference

12 December 2020

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

1 reference

12 December 2020

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

1 reference

12 December 2020

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

12 December 2020

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

12 December 2020

Cancer-specific mutations in PIK3CA are oncogenic in vivo

1 reference

12 December 2020

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

12 December 2020

The multiple roles of PTEN in tumor suppression

1 reference

12 December 2020

Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.

1 reference

12 December 2020

The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma

1 reference

12 December 2020

mTOR-targeted therapy of cancer with rapamycin derivatives

1 reference

12 December 2020

The TOR pathway: a target for cancer therapy

1 reference

12 December 2020

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

12 December 2020

Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism

1 reference

12 December 2020

Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity

1 reference

12 December 2020

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

1 reference

12 December 2020

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)

1 reference

12 December 2020

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

1 reference

12 December 2020

AMPK, the metabolic syndrome and cancer

1 reference

12 December 2020

The biology and clinical relevance of the PTEN tumor suppressor pathway

1 reference

12 December 2020

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization

1 reference

12 December 2020

Oncogenic PI3K deregulates transcription and translation

1 reference

12 December 2020

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

12 December 2020

mTOR regulates cell survival after etoposide treatment in primary AML cells

1 reference

12 December 2020

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

12 December 2020

TOR signaling in growth and metabolism

1 reference

12 December 2020

PI 3-kinase, Akt and cell survival

1 reference

12 December 2020

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

1 reference

12 December 2020

TOR, a central controller of cell growth

1 reference

12 December 2020

NF-kappaB at the crossroads of life and death

1 reference

12 December 2020

ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors

1 reference

12 December 2020

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

1 reference

12 December 2020

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

1 reference

12 December 2020

Regulation of translation initiation by FRAP/mTOR

1 reference

12 December 2020

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

1 reference

12 December 2020

Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin

1 reference

12 December 2020

Antileukemic activity of rapamycin in acute myeloid leukemia.

1 reference

12 December 2020

The protein kinase B/Akt signalling pathway in human malignancy

1 reference

12 December 2020

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

12 December 2020

The phosphoinositide 3-kinase pathway

1 reference

12 December 2020

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

1 reference

12 December 2020

Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells

1 reference

12 December 2020

Ten years of protein kinase B signalling: a hard Akt to follow

1 reference

12 December 2020

Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics

1 reference

12 December 2020

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

1 reference

12 December 2020

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

1 reference

12 December 2020

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

1 reference

12 December 2020

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Identifiers

DOI

10.1007/S11864-006-0038-1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16916489%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference